Literature DB >> 33864549

Pyruvate kinase M2 in chronic inflammations: a potpourri of crucial protein-protein interactions.

Sagarkumar Patel1, Anwesha Das1, Payal Meshram1, Ayushi Sharma1, Arnab Chowdhury1, Heena Jariyal2, Aishika Datta3, Deepaneeta Sarmah3, Lakshmi Vineela Nalla3, Bichismita Sahu1, Amit Khairnar3, Pallab Bhattacharya3, Akshay Srivastava4, Amit Shard5.   

Abstract

Chronic inflammation (CI) is a primary contributing factor involved in multiple diseases like cancer, stroke, diabetes, Alzheimer's disease, allergy, asthma, autoimmune diseases, coeliac disease, glomerulonephritis, sepsis, hepatitis, inflammatory bowel disease, reperfusion injury, and transplant rejections. Despite several expansions in our understanding of inflammatory disorders and their mediators, it seems clear that numerous proteins participate in the onset of CI. One crucial protein pyruvate kinase M2 (PKM2) much studied in cancer is also found to be inextricably woven in the onset of several CI's. It has been found that PKM2 plays a significant role in several disorders using a network of proteins that interact in multiple ways. For instance, PKM2 forms a close association with epidermal growth factor receptors (EGFRs) for uncontrolled growth and proliferation of tumor cells. In neurodegeneration, PKM2 interacts with apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) to onset Alzheimer's disease pathogenesis. The cross-talk of protein tyrosine phosphatase 1B (PTP1B) and PKM2 acts as stepping stones for the commencement of diabetes. Perhaps PKM2 stores the potential to unlock the pathophysiology of several diseases. Here we provide an overview of the notoriously convoluted biology of CI's and PKM2. The cross-talk of PKM2 with several proteins involved in stroke, Alzheimer's, cancer, and other diseases has also been discussed. We believe that considering the importance of PKM2 in inflammation-related diseases, new options for treating various disorders with the development of more selective agents targeting PKM2 may appear.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Cancer; Chronic inflammation; Protein–protein interactions; Pyruvate kinase M2 (PKM2)

Mesh:

Substances:

Year:  2021        PMID: 33864549     DOI: 10.1007/s10565-021-09605-0

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  4 in total

1.  Proteomic analysis of synovial fibroblast-like synoviocytes from rheumatoid arthritis.

Authors:  Xiao-Jun Li; Min Xu; Xiao-Qin Zhao; Jian-Ning Zhao; Fang-Fang Chen; Wei Yu; De-Yu Gao; Bing Luo
Journal:  Clin Exp Rheumatol       Date:  2013-06-05       Impact factor: 4.473

2.  Nitric oxide maintains endothelial redox homeostasis through PKM2 inhibition.

Authors:  Mauro Siragusa; Janina Thöle; Sofia-Iris Bibli; Bert Luck; Annemarieke E Loot; Kevin de Silva; Ilka Wittig; Juliana Heidler; Heike Stingl; Voahanginirina Randriamboavonjy; Karin Kohlstedt; Bernhard Brüne; Andreas Weigert; Beate Fisslthaler; Ingrid Fleming
Journal:  EMBO J       Date:  2019-07-22       Impact factor: 11.598

Review 3.  Epithelial growth factor receptor interacting agents.

Authors:  Jose Baselga; Joan Albanell
Journal:  Hematol Oncol Clin North Am       Date:  2002-10       Impact factor: 3.722

Review 4.  CD44 as a potential diagnostic tumor marker.

Authors:  Nawwaf S Basakran
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.